| Longer-lasting botulinum toxin type A (BoNTA) products are needed for therapeutic and aesthetic indications to maintain stable clinical effects between injections and potentially reduce the frequency of re-treatment. |
| DaxibotulinumtoxinA for Injection (DAXI) is a novel BoNTA utilizing a proprietary stabilizing excipient peptide (RTP004) in place of human serum albumin. |
| DAXI has consistently demonstrated a median effect duration of 24 weeks in the treatment of cervical dystonia and glabellar lines, suggesting that DAXI has the potential to improve the management of both aesthetic and therapeutic conditions. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.